ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2444

Pharmacist-Developed Letters May Enhance Success in Obtaining Insurer Approval for Off-Label Use of Biologics

Jessica F. Farrell1,2,3, Lee S. Shapiro1,2,4, Joel M. Kremer5 and Aixa Toledo-Garcia6, 1Steffens Scleroderma Center, Saratoga Springs, NY, 2The Center for Rheumatology, Albany, NY, 3Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, 4Albany Medical College, Albany, NY, 5Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 6Rheumatology, The Center for Rheumatology, Albany, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Insurance, off-label prescribing, pharmacists and prior authorization

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ARHP): Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose

A growing number of publications suggest that biological DMARDs, predominantly approved for RA, can be efficacious treatment options for several rare rheumatic diseases.  These potentially efficacious treatments are often “out of reach” because of inability to obtain insurance coverage.  Insurers routinely deny coverage of “off-label use” because of the absence of double-blind placebo controlled studies demonstrating efficacy.  This type of evidence is only infrequently available for these rare rheumatic diseases.  The medical director for the insurer often has no familiarity with the disease, the potential consequences of non-treatment or the inadequacy of more accessible therapies.  The addition of a pharmacist as part of a multidisciplinary team can provide an effective resource in successfully navigating the medication prior authorization process.

Methods

Our approach involves the use of a clinical pharmacist in development of comprehensive, evidence-based appeal letters.  These letters are drafted by a clinical pharmacist (PharmD.) and pharmacy interns who perform extensive literature searches including all relevant case reports and clinical data related to disease state and drug therapy.  The PharmD’s then summarize that data as justification for use of therapy.  Appeal letters are then drafted to include an explanation of the patient’s circumstances, disease manifestations, progression, prognosis, as well as the treatment history, and the comprehensive review of current literature on the rationale for and experience with the proposed therapy.  

 

Results

Since January 2009, our pharmacist has drafted and submitted approximately 141 letters.  We have decreased the rate of initial “denials” for off-label use to near zero.  We estimate that we have saved the physicians and support staff approximately 100 hours while achieving the desired outcome for both patients and physicians. We estimate that the average rheumatologist will have a need for between 5- 15 of these letters per quarter. If we calculate the value of physician time based upon billable dollars, we would estimate a net saving for individual physicians of between $1000 and $4000 hours per quarter. Additionally, we have decreased the time associated with the approval process from an average of 4-6 weeks to less than 4 weeks.

Conclusion

The issuance of an evidence based approach to the off-label appeal process has decreased the time associated with approvals and prevented the need for mention of litigation or liability.  Due to time constraints, the ability to provide this level of patient care would not be possible without the assistance of the clinical pharmacist.  The practice of pharmacy has expanded its scope to include extensive clinical training beyond the preparation and dispensing of medication.  Pharmacists have the capacity to provide a wide range of patient-oriented services.  As part of their education, PharmD’s have extensive training in scientific literature evaluation and drug information. Based on our experience and success, it is clear that PharmD’s are an underutilized resource in the ambulatory care setting and can greatly improve patient-care outcomes.


Disclosure:

J. F. Farrell,
None;

L. S. Shapiro,
None;

J. M. Kremer,

Corrona,

1,

Corrona,

4;

A. Toledo-Garcia,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacist-developed-letters-may-enhance-success-in-obtaining-insurer-approval-for-off-label-use-of-biologics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology